{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-189463","form_type":"8-K","ticker":"ALEC","cik":"0001653087","company_name":"Alector, Inc.","filed_at":"2022-07-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.543995+00:00","generated_at":"2026-06-24T19:41:01.669161+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"AbbVie terminates Alector's AL003/CD33 Alzheimer's collaboration","bullets":["AbbVie provided written notice on June 30, 2022 terminating the CD33 (AL003) program.","Alector and AbbVie continue to advance the AL002 (TREM2) program under the existing agreement.","No financial or milestone termination payments disclosed in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-189463","json":"https://secwatch.observer/filing/0001193125-22-189463.json","markdown":"https://secwatch.observer/filing/0001193125-22-189463.md","text":"https://secwatch.observer/filing/0001193125-22-189463.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1653087/000119312522189463/0001193125-22-189463-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1653087/000119312522189463/d317537d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T19:41:01.669161+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}